Inoue M, et al. - Researchers analyzed 306 rheumatoid arthritis (RA) patients who started or switched biologic disease-modifying anti-rheumatic drugs (bDMARDs) for treatment response at 6 months in order to examine agreement between the European League Against Rheumatism (EULAR) response based on ESR or CRP, the Simplified Disease Activity Index 50%, and the Clinical Disease Activity Index 50% response measures. Outcomes revealed good agreement between response measures, with a κ >0.6 in patients treated with tumor necrosis factor inhibitors or cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin fusion protein. IL-6i treatment response was overestimated using EULAR response criteria because the acute-phase reactants improvement largely contributes to the DAS28 improvement